Clinical Cohort Study - TRUST (TRUST)
Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg
Study Overview
Status
Status
Conditions
Conditions
- Atrial Fibrillation
- Arrhythmias, Cardiac
- Ventricular Tachycardia
- Atrial Flutter
- Supraventricular Tachycardia
- Brugada Syndrome
- Atrial Tachycardia
- Long QT Syndrome
- Arrhythmogenic Right Ventricular Dysplasia
- Catecholaminergic Polymorphic Ventricular Tachycardia
- Atrial Cardiomyopathy
- Torsades De Pointes
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Julius Obergassel, MD
- Phone Number: +49 (40) 7410 - 58320
- Email: trust@uke.de
Study Locations
-
-
-
Hamburg, Germany, 20251
- Recruiting
- University Hospital Hamburg-Eppendorf, University Heart and Vascular Center
-
Contact:
- Julius Obergassel, MD
- Phone Number: +49 (40) 7410 - 58320
- Email: trust@uke.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia
- Age ≥ 18 years
- Written informed consent
- Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation
Exclusion Criteria:
- Insufficient knowledge of the German language to understand study documents and interview without translation
- Physical or psychological incapability to cooperate in the investigation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
New onset of cardiac arrhythmias, documented in clinical care and during systematic rhythm monitoring using digital devices.
Time Frame: Follow-up 5 years after inclusion
|
The outcome is measured via remote follow-up using consumer-electronics based remote rhythm monitoring technologies.
Additionally, onset of new cardiac arrhythmias is assessed from medical records collected between follow-up timepoint and inclusion as well as questionnaires and a telephone call with the patient.
|
Follow-up 5 years after inclusion
|
|
Time to a composite of cardiovascular mortality, stroke, acute coronary syndrome and heart failure hospitalization
Time Frame: Follow-up 5 years after inclusion
|
The main primary outcome measures the time until any of death from cardiovascular cause, stroke or TIA or a hospitalization due to heart failure or acute coronary syndrome occurs for the first time after inclusion.
The outcome is measured via telephone and / or in-person follow-up, acquisition of all relevant medical records between inclusion and follow-up timepoint and a questionnaire sent to the patient.
The follow-up can be completed fully electronically according to patient's wish.
|
Follow-up 5 years after inclusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
New onset of heart failure
Time Frame: Follow-up 5 years after inclusion
|
This endpoint is defined as a new diagnosis of heart failure with (milly) reduced or preserved ejection fraction according to ESC guidelines.
The patients medical record will be reassessed at the end of follow-up.
|
Follow-up 5 years after inclusion
|
|
All-cause mortality (Safety Outcome)
Time Frame: Follow-up 5 years after inclusion
|
This endpoint is assessed during the telephone call during remote follow-up and - if not applicable - via consultation of the death registry.
|
Follow-up 5 years after inclusion
|
|
Patient reported quality of life (QOL)
Time Frame: Follow-up 5 years after inclusion
|
As assessed via AF Effect on QualiTy of life survey at the timepoint of follow-up.
|
Follow-up 5 years after inclusion
|
|
Health care utilisation
Time Frame: Follow-up 5 years after inclusion
|
Health care utilisation after inclusion is assessed during the telephone call of the remote follow-up as well as via acquisition of all medical records between follow-up timepoint and inclusion.
|
Follow-up 5 years after inclusion
|
|
Complications of rhythm control therapy (Safety Outcome)
Time Frame: Follow-up 5 years after inclusion
|
This endpoint is assessed during the telephone call of the remote follow-up as well as via acquisition of all medical records between follow-up timepoint and inclusion.
|
Follow-up 5 years after inclusion
|
|
Time to recurrence of the clinical arrhythmia
Time Frame: Follow-up 5 years after inclusion
|
The outcome is measured via remote follow-up using consumer-electronics based remote rhythm monitoring technologies.
Additionally, onset of new cardiac arrhythmias is assessed from medical records collected between follow-up timepoint and inclusion as well as questionnaires and a telephone call with the patient.
|
Follow-up 5 years after inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Paulus Kirchhof, MD, Universitätsklinikum Hamburg-Eppendorf
- Principal Investigator: Andreas Metzner, MD, Universitätsklinikum Hamburg-Eppendorf
- Principal Investigator: Andreas Rillig, MD, Universitätsklinikum Hamburg-Eppendorf
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiac Conduction System Disease
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Genetic Diseases, Inborn
- Disease
- Congenital Abnormalities
- Cardiovascular Abnormalities
- Heart Defects, Congenital
- Brugada Syndrome
- Syndrome
- Atrial Fibrillation
- Cardiomyopathies
- Tachycardia
- Tachycardia, Ventricular
- Tachycardia, Supraventricular
- Arrhythmias, Cardiac
- Long QT Syndrome
- Atrial Flutter
- Arrhythmogenic Right Ventricular Dysplasia
- Torsades de Pointes
Other Study ID Numbers
Other Study ID Numbers
- CCS_TRUST
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.